Functional effects of neuropeptide Y receptors on blood flow and nitric oxide levels in the human nose

被引:24
作者
Cervin, A
Önnerfält, J
Edvinsson, L
Grundemar, L
机构
[1] Univ Lund, Dept Otorhinolaryngol Head & Neck Surg, S-22100 Lund, Sweden
[2] Univ Lund, Dept Internal Med, S-22100 Lund, Sweden
[3] Univ Lund, Dept Clin Pharmacol, S-22100 Lund, Sweden
关键词
D O I
10.1164/ajrccm.160.5.9902102
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
The aim of this study was to examine dose-dependent effects of intranasal application of neuropeptide Y (NPY) on nasal mucosal blood flow, brood content, and intranasal nitric oxide (NO) concentration. Blood flow was measured by laser Doppler flowmetry (LDF) and blood content by rhinomanometry. Mucosal biopsies were taken for investigation of Y1 and Y2 receptor mRNA expression, using the reverse transcriptase-polymerase chain reaction (RT-PCR). Intranasal application of NPY evoked a dose-dependent reduction of nasal mucosal blood flow. Maximal vasoconstriction, seen at 12 nmol, was -37.5 +/- 6.2%, p < 0.05 (n = 9). The vasoconstrictive effect developed within 2 to 4 min and lasted > 17 min. NPY evoked a dose-dependent reduction of nasal airway resistance (NAR) on the ipsilateral side. Maximal decrease was -24.0 +/- 10.0% at 12 nmol, p < 0.05 (n = 9). There was a decrease in nasal NO production on the ipsilateral side after application of NPY 12 nmol (-7.4 +/- 1.2%, p < 0.05, n = 8). RT-PCR products corresponding to Y1 receptor but not Y2 receptor mRNA were obtained from biopsies of the nasal mucosa. In conclusion, NPY is a potent vasoconstrictor in the human nose reducing mucosal blood flow, as well as the blood content. The effect is probably mediated via Y1 receptors. NPY receptor agonists may prove beneficial in the treatment of the congested nose in allergic or vasomotor rhinitis.
引用
收藏
页码:1724 / 1728
页数:5
相关论文
共 34 条
[1]  
Arnal JF, 1997, CLIN EXP ALLERGY, V27, P358
[2]   NEUROPEPTIDE-Y (NPY) IN HUMAN NASAL-MUCOSA [J].
BARANIUK, JN ;
CASTELLINO, S ;
LUNDGREN, JD ;
GOFF, J ;
MULLOL, J ;
MERIDA, M ;
SHELHAMER, JH ;
KALINER, MA .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1990, 3 (02) :165-173
[3]   NEUROPEPTIDE-Y IS A VASOCONSTRICTOR IN HUMAN NASAL-MUCOSA [J].
BARANIUK, JN ;
SILVER, PB ;
KALINER, MA ;
BARNES, PJ .
JOURNAL OF APPLIED PHYSIOLOGY, 1992, 73 (05) :1867-1872
[4]   Neuropeptide Y potentiates noradrenaline-induced contraction through the neuropeptide Y Y-1 receptor [J].
Bergdahl, A ;
Nilsson, T ;
Cantera, L ;
Nilsson, L ;
Sun, XY ;
Hedner, T ;
Erlinge, D ;
Valdemarson, S ;
Edvinsson, L .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 316 (01) :59-64
[5]   RHINOMANOMETRY .2. A SYSTEM FOR NUMERICAL DESCRIPTION OF NASAL AIRWAY-RESISTANCE [J].
BROMS, P ;
JONSON, B ;
LAMM, CJ .
ACTA OTO-LARYNGOLOGICA, 1982, 94 (1-2) :157-168
[6]   NEUROPEPTIDE-Y IN THE RABBIT MAXILLARY SINUS MODULATES CHOLINERGIC ACCELERATION OF MUCOCILIARY ACTIVITY [J].
CERVIN, A ;
LINDBERG, S ;
MERCKE, U ;
UDDMAN, R .
ACTA OTO-LARYNGOLOGICA, 1992, 112 (05) :872-881
[7]   NEUROPEPTIDE-Y 16-36 INHIBITS MUCOCILIARY ACTIVITY BUT DOES NOT AFFECT BLOOD-FLOW IN THE RABBIT MAXILLARY SINUS INVIVO [J].
CERVIN, A .
REGULATORY PEPTIDES, 1992, 39 (2-3) :237-246
[8]   Expression of calcitonin gene-related peptide(1) receptor mRNA in human trigeminal ganglia and cerebral arteries [J].
Edvinsson, L ;
Cantera, L ;
JansenOlesen, I ;
Uddman, R .
NEUROSCIENCE LETTERS, 1997, 229 (03) :209-211
[9]   NEUROPEPTIDE-Y - CEREBROVASCULAR INNERVATION AND VASOMOTOR EFFECTS IN THE CAT [J].
EDVINSSON, L ;
EMSON, P ;
MCCULLOCH, J ;
TATEMOTO, K ;
UDDMAN, R .
NEUROSCIENCE LETTERS, 1983, 43 (01) :79-84
[10]   Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant [J].
Ferguson, EA ;
Eccles, R .
ACTA OTO-LARYNGOLOGICA, 1997, 117 (04) :614-617